As a service to our authors and readers, this journal provides supporting information supplied by the authors. Such materials are peer reviewed and may be re-organized for online delivery, but are not copy-edited or typeset. Technical support issues arising from supporting information (other than missing files) should be addressed to the authors.

emmm201302796.reviewer_comments.pdfPDF document375KReview Process File
emmm201302796-sm-0002-SuppFig-S1.pdfPDF document754K

Figure S1. VPA stimulates H-1PV-mediated oncolysis in cervical and pancreatic derived cancer cell lines.

Figure S2. H-1PV/VPA co-treatment is not harmful to normal primary human cells.

Figure S3. The HDAC inhibitor NaB synergizes with H-1PV in killing HeLa cells by inducing ROS accumulation and DNA damage.

Figure S4. NaB increases NS1-mediated cytotoxicity.

Figure S5. NaB treatment increases H-1PV expression.

Figure S6. VPA increases H-1PV production in cervical carcinoma derived cell lines.

Figure S7. VPA enhances H-1PV oncosuppressive capacity in the HeLa xenograft rat model.

Figure S8. Virus biodistribution in H-1PV/VPA-co-treated animals after tumour eradication.

Figure S9. Analysis of HeLa all-derived tumours for the presence of the human papillomavirus genome.

Figure S10. Complete remission of established AsPC-1 tumours upon combined treatment with H-1PV and VPA.

Figure S11. Morphological analysis of AsPC-1 cell tumour xenografts.

Figure S12. H-1PV/VPA co-treatment leads to complete eradication of established primary tumour material xenografts.

Table S1. Summary of statistical analysis results obtained for cancer cell lines co-treated with H-1PV and VPA.

Table S2. Summary of statistical analysis results obtained for HeLa and AsPC-1 animal experiments.

emmm201302796-SourceData-Fig1.pdfPDF document252KSource Data for Figure 1
emmm201302796-SourceData-Fig2.pdfPDF document54KSource Data for Figure 2
emmm201302796-SourceData-Fig3.pdfPDF document66KSource Data for Figure 3
emmm201302796-SourceData-Fig5.pdfPDF document84KSource Data for Figure 5
emmm201302796-SourceData-Fig6.pdfPDF document155KSource Data for Figure 6
emmm201302796-SourceData-Fig8.pdfPDF document80KSource Data for Figure 8
emmm201302796-SourceData-Fig9.pdfPDF document80KSource Data for Figure 9
emmm201302796-SourceData-FigS3.pdfPDF document44KSource Data for Figures S3
emmm201302796-SourceData-FigS4.pdfPDF document57KSource Data for Figures S4
emmm201302796-SourceData-FigS5.pdfPDF document81KSource Data for Figures S5

Please note: Wiley Blackwell is not responsible for the content or functionality of any supporting information supplied by the authors. Any queries (other than missing content) should be directed to the corresponding author for the article.